Company profile: Dako
1.1 - Company Overview
Company description
- Provider of reagents, instruments, and software for cancer diagnostics to hospital and research laboratories, offering pathology solutions including diagnostic antibodies, IHC/ISH and flow cytometry reagents; staining and image analysis instruments; molecular and companion diagnostics; and pharmacodiagnostic kits (pharmDx).
Products and services
- Companion diagnostics: Dako Denmark delivers kit-based pharmacodiagnostic tests (pharmDx) that determine patient suitability for particular cancer treatments, supporting precise therapy selection in hospital and research laboratory settings
- Diagnostic antibodies: Dako Denmark produces clinical-grade antibodies for accurate cancer diagnostics, optimized for immunohistochemistry (IHC) pathology assays in hospital and research laboratory workflows
- Pathology systems: Dako Denmark architects laboratory-grade pathology systems combining diagnostic antibodies, reagents, automated staining instruments, image-analysis instruments, and cancer-diagnostics software for hospital and research laboratories
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Dako
Highlight Therapeutics
HQ: Spain
Website
- Description: Provider of an RNA-based immuno-oncology therapy, BO-112, designed to initiate an immune response against 'cold' tumors, making them 'hot' and visible to the immune system. Services include clinical development and trials (successful Phase 1 monotherapy, Phase 1b with anti-PD1), collaborations with Merck & Co and UCLA, and R&D into BO-112’s mechanism where checkpoint inhibitors are ineffective.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Highlight Therapeutics company profile →
Theraclone Sciences
HQ: United States
Website
- Description: Provider of novel therapeutic antibodies and an antibody discovery platform for infectious diseases and inflammation. Offers a comprehensive screening technology to identify rare human monoclonal antibodies, HIV broadly neutralizing fully human antibodies licensed to Gilead for HIV-cure regimens, and platform technology licensed to OncoResponse for oncology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Theraclone Sciences company profile →
MDxHealth
HQ: United States
Website
- Description: Provider of molecular diagnostics and epigenetic tests for cancer assessment and personalized treatment, including Select mdx (urine test to identify men at risk for aggressive prostate cancer before an initial biopsy), Confirm mdx (tissue test for risk of undetected clinically significant prostate cancer after a negative biopsy), Genomic Prostate Score (predicts disease aggressiveness), and Resolve mdx (PCR UTI test with personalized antibiotic options).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MDxHealth company profile →
Nereus Pharmaceuticals
HQ: United States
Website
- Description: Provider of therapeutics discovery and development focused on oncology, infectious diseases, and inflammation, leveraging marine microbiology technologies to identify and develop drug candidates, including NPI-2358, a tumor vascular disrupting agent.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nereus Pharmaceuticals company profile →
Potenza Therapeutics
HQ: United States
Website
- Description: Provider of preclinical-stage biotechnology oncology programs that utilize the body's own immune system to seek out, recognize, and destroy tumors through diverse mechanisms influencing tumor immunity; founded in 2014 and headquartered in Cambridge, Massachusetts.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Potenza Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Dako
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Dako
2.2 - Growth funds investing in similar companies to Dako
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Dako
4.2 - Public trading comparable groups for Dako
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →